Company / Current Liabilities
Celldex Therapeutics, Inc. Current Liabilities History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$51.0M
FY2025
5-year range
$16.5M / $51.0M
FY2021-FY2025
Trend
+29.1%
vs FY2024
Sector context
#143 of 160
Health Care
What the data says
Celldex Therapeutics, Inc.'s current liabilities of $51M is lower than 89% of companies in the Health Care sector (FY2025). Current Liabilities has increased for 6 consecutive years, from $12M in FY2019 to $51M in FY2025.
Based on SEC 10-K filings.
$51M in FY2025 with a 5-year CAGR of +29.1%.
Increased from $31M to $51M over the past 2 years.
Health Care sector context is included.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +39.9%
- 5-Year CAGR
- +29.1%
- 10-Year CAGR
- -
Sector benchmark
Top 11% in Health CareTop 11% of 160This company $51.0M Sector average $4.5B
▼
-98.9% below sector average
Key checks
Key Insights
- Celldex Therapeutics, Inc.'s current liabilities has grown for 6 consecutive years.
- 5-year CAGR of +29.1%, indicating consistent growth.
- In FY2025, current liabilities increased 29.1% year-over-year.
- Ranks #143 out of 160 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.40 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $51.0M | +29.1% |
| FY2024 | $39.5M | +26.9% |
| FY2023 | $31.1M | +67.2% |
| FY2022 | $18.6M | +12.6% |
| FY2021 | $16.5M | +16.3% |
| FY2020 | $14.2M | +22.0% |
| FY2019 | $11.6M | -7.6% |
| FY2018 | $12.6M | -54.6% |
| FY2017 | $27.7M | -21.3% |
| FY2016 | $35.2M | +16.5% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026